Related Experiment Video
Updated: Aug 11, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Radical prostatectomy versus brachytherapy for early-stage prostate cancer
1Department of Urology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA. malexianu@hotmail.com
Journal of Endourology
|July 26, 2000
Summary
Brachytherapy and radical prostatectomy are prostate cancer treatments. Brachytherapy has lower costs and potentially fewer side effects, but a slightly higher disease progression rate than surgery.
Area of Science:
- Oncology
- Urology
- Medical Technology
Background:
- Prostate cancer treatment decisions involve cure potential, toxicity, morbidity, quality of life, and costs.
- Traditional options include radical prostatectomy, external-beam radiation, and watchful waiting.
- Brachytherapy has emerged as a significant technological advancement in prostate cancer treatment.
Purpose of the Study:
- To compare brachytherapy and radical prostatectomy for prostate cancer.
- Evaluation criteria include cancer control, complication rates, and cost-effectiveness.
Main Methods:
- Comparative analysis of brachytherapy and radical prostatectomy series.
- Data sourced from leading medical centers specializing in each procedure.
Main Results:
- Radical prostatectomy showed a 7-year success rate of 97.8% for early-stage, low-grade prostate cancer.
- Brachytherapy demonstrated a 7-year success rate of 79%.
- Brachytherapy patients experienced higher rates of erectile dysfunction and slight urethral toxicity, but maintained continence; costs were lower for brachytherapy.
Conclusions:
- Brachytherapy may be associated with a slightly increased risk of disease progression compared to surgery.
- Side effects of brachytherapy are generally acceptable and potentially less severe than surgical complications.
- Long-term follow-up data are essential to fully establish the comparative roles of brachytherapy and radical prostatectomy in early-stage prostate cancer management.
